Eric Devroe
Eric Devroe, Ph.D., is Chief Operating Officer at Acrivon Therapeutics, Inc. Eric is an executive and entrepreneur with significant experience helping found, launch, and build new life science companies. Most recently, he served as Founder & CEO of Xione Therapeutics, Inc., an oncology focused spin-out of The University of Texas MD Anderson Cancer Center. Prior to Xione, he was Strategic Advisor, Therapeutics Discovery at MD Anderson Cancer Center, and the Founder and CEO of Opsonix, Inc., an infectious disease focused spin-out of the Wyss Institute at Harvard University. Prior to Opsonix, he served as Executive Director of Strategic Alliances at MD Anderson Cancer Center. Earlier in his career he served as VP, Business & Strategy Development at Metamark Genetics, Inc., and an Associate at Flagship Pioneering. He holds a B.S. in Microbiology from the University of Texas at Austin and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.